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Abstract
Background: Colorectal cancer (CRC) is one of the most frequently occurring cancers in Japan, and thus a wide range of methods have been deployed to study the 
molecular mechanisms of CRC. In this study, we performed a comprehensive analysis of CRC,   incorporating copy number aberration (CRC) and gene expression data. 
For the last four years, we have been collecting data from CRC cases and organizing the information as an “omics” study by integrating many kinds of analysis into a 
single comprehensive investigation.
In our previous studies, we had experienced difficulty in finding genes related to CRC, as we observed higher noise levels in the   expression data than in the data for other 
cancers.
Because chromosomal aberrations are often observed in CRC, here, we have performed a combination of CNA analysis and expression analysis in order to identify some 
new genes responsible for CRC.
This study was performed as part of the Clinical Omics Database Project at Tokyo Medical and Dental University. The purpose of this study was to investigate the 
  mechanism of genetic instability in CRC by this combination of expression analysis and CNA, and to   establish a new method for the diagnosis and treatment of CRC.
Materials and methods: Comprehensive gene expression analysis was performed on 79 CRC cases using an Affymetrix Gene Chip, and comprehensive CNA   analysis 
was performed using an Affymetrix DNA Sty array. To avoid the contamination of cancer tissue with normal cells, laser micro-dissection was performed before DNA/RNA 
extraction. Data analysis was performed using original software written in the R language.
Result: We observed a high percentage of CNA in colorectal cancer, including copy number gains at 7, 8q, 13 and 20q, and copy number losses at 8p, 17p and 18. Gene 
expression analysis provided many candidates for CRC-related genes, but their association with CRC did not reach the level of statistical significance. The combination 
of CNA and gene expression analysis, together with the clinical information, suggested UGT2B28, LOC440995, CXCL6, SULT1B1, RALBP1, TYMS, RAB12, RNMT, 
ARHGDIB, S1000A2, ABHD2, OIT3 and ABHD12 as genes that are possibly associated with CRC. Some of these genes have already been reported as being related to 
CRC. TYMS has been reported as being associated with resistance to the anti-cancer drug 5-fluorouracil, and we observed a copy number increase for this gene. RALBP1, 
ARHGDIB and S100A2 have been reported as oncogenes, and we observed copy number increases in each. ARHGDIB has been reported as a metastasis-related gene, 
and our data also showed copy number increases of this gene in cases with metastasis.
Conclusion: The combination of CNA analysis and gene expression analysis was a more effective method for finding genes associated with the clinicopathological 
classification of CRC than either analysis alone. Using this combination of methods, we were able to detect genes that have already been associated with CRC. We also 
identified additional candidate genes that may be new markers or targets for this form of cancer.
Keywords: colorectal cancer, clinical omics, microarray, copy number aberrationYoshida et al
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Background
Colorectal Cancer (CRC) has now become the third 
leading cause of death in Japan, and is one of the cancers 
with highest incidence in women.1 In 2006, 22,547 men 
and 18,834 women died from CRC in Japan. Surgical 
operation is the most common treatment, but chemo-
therapy is also performed in Western countries. New 
drug targets have been developed recently, including 
oncogenes, anti-oncogenes, signal-transduction factors 
and apoptosis factors, and some of the drugs related 
to these factors are under clinical trial. Meanwhile, 
drug resistance is increasingly becoming an issue for 
chemotherapy.
Since 2005, we have been collecting   comprehensive 
clinical information and omics   information to establish 
our Integrated Clinical Omics Database (iCOD).2,3 We 
have  collected  about  200  hepatocellular  carcinoma 
cases,  200  CRC  cases  and  150  oral  cancer  cases. 
The database can be accessed at http://omics.tmd.ac.jp/. 
We are collecting comprehensive clinical information 
from patient records held at the hospital, and by inter-
views with patients. The data is anonymized and stan-
dardized for statistical analysis. The surgical specimens 
are stored, and genomic (single nucleotide polymor-
phisms (SNPs) and CNA), epigenomic, transcriptomic 
(mRNA  and  micro-RNA)  and  proteomic  analysis 
are performed for each case. Our goal is to integrate 
comprehensive information to determine the relation 
between omics and clinical pathology by a systematic 
biomedical approach.
A lot of work has been done on molecular   biological 
researches in CRC, and it is known that a specific 
sequence of several genes change   sequentially   during 
the  development  of  CRC  i.e.  APC,  beta-catenin, 
K-ras, p53, TDF-beta receptor, Smad2 and Smad4. 
This  is  called  the  adenoma-carcinoma  sequence. 
A change in APC is observed in the early stage of this 
sequence, and thus APC is often called a gatekeeper 
gene for CRC.
CRC  is  considered  to  develop  through  two 
  pathways: 85% of cases arise due to chromosomal 
instability (CIN), and 15% arise due to   microsatellite 
instability  or  replication  errors.4–7  Copy  number 
  aberrations are often observed in CRC,8–16 including 
gains at 7, 8q, 13 and 20q, and losses at 8p, 17p and 
18. Some of these observations are related to the grade 
or metastasis level of CRC. Comprehensive analysis 
of these changes has previously been performed by 
comparative genomic hybridization or array compar-
ative genomic hybridization, but a new method using 
SNP array has recently become possible.17–20
samples
We obtained fresh-frozen tissue samples from 70 CRC 
patients (43 males and 27 females) who had   undergone 
surgical  resection  at  Tokyo  Medical  and    Dental 
  University  Hospital  Faculty  of  Medicine  (Tokyo, 
Japan) between November 2005 and August 2007. This 
research project was reviewed and approved by insti-
tutional  review  board  guidelines.  Informed  consent 
was obtained from all patients via the standard proto-
cols of the institution. The tumors were located in the 
colon (46 samples) and rectum (24 samples). Normal 
tissue was obtained from each patient, taken from at 
the adjacent region of the colon or rectum, and used as 
the control sample. All resected specimens were col-
lected in cryotubes, frozen and stored at -80 °C until 
the DNA and RNA analyses were performed.
DnA Isolation
Tumors  were  microdissected  by  removing  the 
  surrounding  non-neoplastic  tissue.  Tumor  DNA 
was extracted and purified using a QIAamp DNA 
Micro Kit (QIAGEN, Valencia, CA) according to the 
  manufacturer’s  instructions.  Contaminated  RNAs 
were eliminated using RNase A during the   purification 
process. Non-neoplastic tissues were homogenized 
in  microtubes.  Non-neoplastic  tissue  DNA  was 
extracted and purified using a QIAamp DNA Mini 
Kit  (QIAGEN)  according  to  the    manufacturer’s 
instructions.  Contaminated  RNAs  were  eliminated 
using  RNase  A  during  the  purification  process. 
According  to  the  Mapping  500  K  Assay  Manual 
supplied by Affymetrix (Santa Clara, CA), the mini-
mum amount of genomic DNA required was 250 ng. 
Therefore,  only  purified  DNA  samples  containing 
more than 250 ng of genomic DNA, as determined 
by  a    NanoDrop    spectrophotometer    (NanoDrop 
  Technologies, Wilmington,  DE),  were  used  in  the 
subsequent  experiments.  For  each  sample,  quality 
controls, which included confirming DNA degrada-
tion and contamination of RNAs, were performed by 
running 1% agarose gel electrophoresis with lambda 
DNA/Hind fragments.Clinical omics analysis of colorectal cancer
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snp Array Analysis
The experiment was performed by strictly   following the 
assay manual and using a GeneChip® Human   Mapping 
250 K Sty array (Affymetrix). The   concentration of 
the starting materials was standardized by diluting 
genomic DNA samples to 50 ng/µl with a reduced 
EDTA-TE buffer. Since the Mapping 500 K Array set 
consists of two types of arrays, there are two alterna-
tives of enzymes, which are Nsp I and Sty I. In this 
study, we used Sty I for digesting genomic DNA and 
used adaptor for Sty I in the PCR reaction following 
the manufacturers manual, which includes reaction at 
94 °C 3 min, (94 degree 30 sec : 60 degree 45 sec : 
68 degree 15 sec) × 30 cycles, 68 degree 7 min, and 
4 degree hold. Amplicons were   fragmented after the 
purification,  followed  by    labeling  reaction.  After 
16 hours of hybridization at 49 °C, the microarrays 
were transferred to a Fluidic Station 450 (Affymetrix), 
which is a totally automated system, for the washing 
and staining steps. After fluorescence staining, the 
microarray images were scanned by an Affymetrix 
laser scanner.
Data Analyses of snp Arrays
The microarray data from the laser scanner was used 
for copy number analysis with a Chromosome Copy 
Number Analysis Tool (Affymetrix). The copy   number 
for each SNP probe set taken from a tumor sample 
was calculated by comparing the probe intensity to 
the reference probe intensity from   non-neoplastic tis-
sue, and creating a list of the genome-wide copy num-
ber  data.  Genome-wide  CNA  analysis  was    carried 
out for the gene information combined with the copy 
numbers  in  order  to  identify  the  overall  tendency 
of the chromosomal CNAs over the whole human 
genome in CRCs. Software written in the R language 
(http://www.r-project.org/) was used to perform this 
visualization of CNAs across the chromosomes and 
for the rest of the data analyses.
Total RnA Isolation
Tumors were microdissected by removing the sur-
rounding  non-neoplastic  tissue.  The  total  RNA 
was extracted and purified using an RNeasy micro 
kit  (QIAGEN)  with  on-column  DNase  digestion, 
according  to  the  manufacturer’s  instructions.  The 
integrity of the total RNA we obtained was assessed 
using a Bioanalyzer RNA 6000 Nano Assay (Agilent 
  Technologies, Palo Alto, CA). Samples with an RNA 
Integrity Number (RIN) greater than 5.0 were used 
for the rest of the experiments.
Microarray Analysis
Using 100 ng of total RNA, cRNA was prepared using 
two-cycle target labeling and control reagents, namely 
Affymetrix P/N 900494 (Affymetrix). The experiment 
was  performed  using  a  GeneChip® Human Genome 
U133 Plus 2.0 Array (Affymetrix) in strict adherence to 
the assay manual. The 70   output data files (CEL files ) 
obtained by this process were then normalized with the 
robust multi-array average method using R 2.4.1 statis-
tical software (http://www.r-project.org/) together with 
the “Affy” package from BioConductor (http://www.
bioconductor.org/).  Estimated  gene  expression  levels 
were  calculated  as  log2-transformed  values,  and  62 
  control probe sets were removed for further analysis. In 
order to identify differently expressed genes associated 
with clinico-pathological characteristics, we performed 
exact Wilcoxon   rank-sum tests available from the in 
“Coin” package. Fold-change values (FC) were also 
calculated using the ratio of geometric means of gene 
expression levels in each patient group.
Gene sets
Our  CNA  data  was  also  statistically  analyzed  to 
investigate the association between the CNA and the 
prognosis of CRC. Fisher’s exact test was applied 
to multiple conditions, such as T/N/M classification 
and recurrence. All genes with P-values , 0.01 were 
classified into Gene Set I.
Statistically significant differences in gene expres-
sion were assessed using the Wilcoxon exact rank-sum 
test from the exactRankTests package. The Wilcoxon 
exact rank-sum test was also applied to multiple con-
ditions, such as T/N/M classification and recurrence. 
Genes with P-values , 0.05 and FC . 1.5 were clas-
sified into Gene Set II.
Genes included in both Gene Set I and Gene Set II 
were defined as Gene Set III.
Results
Analysis of copy number variations
Based on the copy number variation analysis of 70 cases, 
we found copy number increases in   chromosome 7, Yoshida et al
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8q, 13 and 20q, and copy number decreases in 8p, 17p 
and 18 (Fig. 1). In particular, copy number increases 
in  chromosome  20q  and  decreases  in  chromosome 
18q were identified in over 80% of cases. Gene ampli-
fications were also involved in these chromosomes: 
for example, the   CRC-associated gene snail homolog 
1 (SNAI1) exists in chromosome 20q and is deleted in 
colorectal carcinoma (DCC) in   chromosome 18q.
selection of gene set I (from the 
relationship between copy number 
variation and clinico-pathological factors)
We performed Fisher’s exact tests in order to   examine 
the  significance  of  any  associations  between  the 
copy numbers of all genes (26,376 genes) and clini-
co-pathological factors, and selected the statistically 
significant  genes  (P  ,  0.01)  (Gene  Set  I). These 
genes were used in subsequent analyses for selecting 
Gene Set III.
In one association analysis between T   classification 
(T1 and T2 vs. T3 and T4) and copy number   variations, 
three genes showed significant copy   number increases 
and 28 genes showed significant copy number decreases. 
These genes were categorized as Gene Set I-TA.
In  another  association  analysis  between T  clas-
sification (T1, T2 and T3 vs. T4) and copy number 
variations, 407 genes showed significant copy num-
ber increases and 209 genes showed significant copy 
number decreases. These genes were categorized as 
Gene Set I-TB.
In  association  analysis  between  N    classification 
(N0  vs.  N1  and  N2)  and  copy  number  varia-
tions,  145  genes  showed  significant  copy  number 
increases  and  88  genes  showed  significant  copy 
number decreases. These genes were categorized as 
Gene Set I-N.
In  association  analysis  between  M  classi-
fication  (M0  vs.  M1)  and  copy  number  varia-
tions, 170 genes showed significant copy number 
increases and 124 genes showed significant copy 
number decreases. These genes were categorized as 
Gene Set I-M.
In association analysis between recurrence (Re0: 
no recurrence vs. Re1: recurrence) and copy number 
variations, 391 genes showed significant copy num-
ber increases and 311 genes showed significant copy 
number decreases. These genes were categorized as 
Gene Set I-Re.
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Figure 1. Percentage of CnA at each probe set position in 70 CrC cases sorted by chromosomes.  
note: Percentages of cases with a copy number aberration (red: gain; green: loss) at each probe set are shown as a bar-graph.
selection of gene set II (from the 
relationship between gene expressions 
and clinico-pathological factors)
All  70  cases  were  classified  into  two  groups  by 
  clinicopathological criteria, and Wilcoxon exact rank 
tests using the expression data of each gene were per-
formed. We selected some statistically significant genes 
(P-value , 0.05 and FC . 1.5, or P-value , 0.05 and 
FC , 0.67) and analyzed these genes as Gene Set II.
As to T classification (T1 and T2 vs. T3 and T4), 
29 genes were significantly up-regulated and 89 genes 
were  significantly  down-regulated.  We  categorized 
these genes as Gene Set II-TA and used them in sub-
sequent analyses.
As to T classification (T1, T2 and T3 vs. T4), 30 genes 
were significantly up-regulated and 52 genes were sig-
nificantly down-regulated. We categorized these genes 
as Gene Set II-TB.
As to N classification (N0 vs. N1 and N2), 39 genes 
were significantly up-regulated and 26 genes were 
significantly  down-regulated. We  categorized  these 
genes as Gene Set II-N.
As to M classification (M0 vs. M1), 100 genes 
were significantly up-regulated and 46 genes were 
significantly  down-regulated. We  categorized  these 
genes as Gene Set II-M.
As  to  recurrence  classification  (Re0  vs.  Re1), 
93 genes were significantly up-regulated and 54 genes 
were  significantly  down-regulated.  We  categorized 
these genes as Gene Set II-Re.
selection of gene set III (from the 
relationship between copy number 
variations and gene expressions)
The  genes  that  appeared  in  both  Gene  Set  I  and 
Gene Set II were classified as Gene Set III. Genes in 
this third set had parallel expression and copy num-
ber  change  (e.g.  copy  number  increase  paralleled 
  up-regulated expression). The subcategorirs in   Gene 
Set III followed the same clinico-pathological label-
ing system as Gene Sets I and II. Figure 2 compares 
the expression differences for expression differences 
for each gene in Gene Set III and Table 2 lists the total 
number of genes in each set. Table 3 lists the genes Clinical omics analysis of colorectal cancer
Cancer Informatics  2010:9  153
Table  1.  Clinico-pathological  data  for  70  primary  CrC 
cases.
Factor patients (n = 70) percentage 
(%)
Age (years) 65.7 ± 10.9  
(range: 33–87)
gender
  Male 43 61.4 
  Female 27 38.6 
Position
  Colon 46 65.7 
  rectum 24 34.3 
stage
 1 9 12.9 
 2 25 35.7 
 3 23 32.9 
 4 13 18.6 
T
 1 1 1.4 
 2 12 17.1 
 3 28 40.0 
 4 29 41.4 
n
 0 39 55.7 
 1 23 32.9 
 2 8 11.4 
M
 0 57 81.4 
 1 13 18.6 
recurrence
  re- 50 71.4 
  re+ 20 28.6 
appearing  in  Gene  Set  III  by  clinico-pathological 
classification.
In  Gene  Set  III-TA,  no  genes  showed  both  a 
copy number increase and up-regulated expression 
(FC . 1.5 and P , 0.05; group 1); however, UDP 
glucuronosyltransferase  2  family  polypeptide  B28 
(UGT2B28) showed both a copy number decrease 
and  down-regulated  expression  (FC  .  0.67  and 
P , 0.05; group 2).
In  Gene  Set  III-TB,  group  1  contained  a  hypo-
thetical  gene  supported  by  BC034933;  BC068085 
(LOC440995)  was  identified.  Group  2  contained 
chemokine  (C-X-C  motif)  ligand  6  (granulocyte 
chemotactic protein 2) (CXCL6); the sulfotransferase 
family;  cytosolic,  1B,  member  1  (SULT1B1)  and 
chemokine (C-X-C motif) ligand 3 (CXCL3).
In Gene Set III-N, group 1 contained ralA binding 
protein 1 (RALBP1); thymidylate synthetase (TYMS); 
RAB12,  a  member  of  the  RAS  oncogene  family 
(RAB12); and RNA (guanine-7-)   methyltransferase 
(RNMT); group 2 contained no genes.
In Gene Set III-M, group 1 contained no genes, 
and group 2 contained Rho GDP dissociation inhibi-
tor (GDI) beta (ARHGDIB).
In Gene Set III-Re, group 1 contained S100 cal-
cium binding protein A2 (S100A2) and abhydrolase 
domain  containing  2  (ABHD2),  and  group  2  con-
tained oncoprotein induced transcript 3 (OIT3) and 
abhydrolase domain containing 12 (ABHD12).
Thus a total of 14 genes were assigned to Gene Set 
III, which was a much smaller number of genes than 
assigned to Gene Set I or Gene Set II.
When we remove fold change from the analysis, 
the number of selected genes increases dramatically. 
As many of the genes showed no correlation between 
copy number and gene expression, we defined Gene 
Set III in terms of both FC and P-value.
Discussion
The results of the CNA analysis (Fig. 1) clearly show 
that copy number gains were often observed in chro-
mosomes  7,  8q,  13  and  20q.  Copy  number  losses 
were also frequently observed in chromosomes 8p, 
17p, and 18. These results match the observations 
in other institutes and even in other countries,8–16 so 
we  believe  these  characteristics  can  be  considered 
to apply to CRC worldwide, despite differences in 
genetic backgrounds or lifestyles.
We  observed  a  copy  number  gain  in  SNAI1,  a 
CRC-related gene, in more than 85% of cases, as a 
CRC-related  gene.  SNAI1  is  located  at  20q13.1-
q13.2, and is said to play a role in the regulation of the 
cell adhesion protein E-cadherin (CDH1).21 SNAI1 is 
also plays a role in phosphorylation through Axin and 
GSK-3beta for degradation of beta-catenin in protea-
somes in the Wnt-signaling pathway.22 DCC is located 
at 18q21.3, and it is one of the membrane proteins with 
netrin-1 (NTN1) as a ligand. DCC of SNAI1 makes an 
apoptotic signal to the cell when no ligand is bound, 
and NTN1 inhibits its signal, thus DCC and NTN1 
are thought to be one of the cancer suppressor genes. 
Repression  of  DCC  is  observed  not  only  in  CRC, 
but also in other tumors.23 The copy number changes 
observed in the present study also support these previ-
ous findings.
Many genes were extracted as those related to the 
clinico-pathological  classifications  using  Fisher’s Yoshida et al
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Figure 2. (Continued)
test in Gene Set I (P , 0.001). However, most of 
them were unknown open reading frames or pseudo-
genes.  Even  it  was  difficult  to  establish  an  asso-
ciation between the annotated genes and CRC. A 
similar analysis was performed for Gene Set II using 
the Wilcoxon exact rank test for clinico-patholog-
ical classification, and some genes were extracted 
(P , 0.05) and FC . 1.5. However, this was insuf-
ficient to infer a relationship with CRC. For this 
reason, we performed a combined analysis of Gene 
Sets I and II.
We were able to extract several genes by this com-
bined analysis, and defined these as Gene Set III. We 
investigated these genes further by their function and 
by a search of the literature.
Gene set III-TA
UGT2B28 was extracted as Gene Set III-TA (T1 and T2 
vs. T3 and T4), which showed copy number loss and 
a decrease in expression level (FC , 0.67, P , 0.05). 
UGT2B28 is located at 4q13.2, and is a membrane 
protein in cytosolic microsomes as one of the sub-
types of uridine diphospho-glucuronosyl-transferases 
(UGTs).  UGTs  are  enzymes  for  glucronization  of 
foreign molecules for detoxification. UGT2B plays a 
role in the metabolism of bilic acid, all-trans retinoic 
acid (ATRA), non-steroidal anti-inflammatory drugs 
(NSAIDs), flavonoids and steroids.24,25 Substrates of 
UGT2B generally have an inhibitory effect for CRC, 
but  down-regulation  of  UGT2B28  may  lead  to  an 
abnormal environment in the cell.Clinical omics analysis of colorectal cancer
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Figure 2. (Continued)
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Figure  2.  expression  comparison  of  each  genes  in  gene  set  III.  expression  differences  are  shown  for  each  gene,  compared  by  each  group.   
gene set III-TA (T1 and T2 vs. T3 and T4): A) UgT2B28, B) LOC440995, c) CXCL6, D) sULT1B1; gene set III-TB (T1, T2 and T3 vs. T4 ): e) CXCL3,   
F) rALBP1, G) TYMs, H) rAB12; gene set III-n (n0 vs. n1 and n2): I) rnMT; gene set III-M (M0 vs. M1): J) ArhgDIB, K) s100A2, L) ABhD2, M) OIT1; 
gene set III-re (recurrence vs. non-recurrence): n) ABhD12.
notes: *P , 0.05; **P , 0.01; ***P , 0.001.
Gene set III-TB
LOC440995 was extracted as Gene Set III-TB (T1, 
T2 and T3 vs. T4), which showed copy number gain 
and a high expression level (FC . 1.5 and P , 0.05). 
CXCL6,  SULT1B1  and  CXCL3  genes  were  also 
extracted in Gene Set III as copy number loss and 
expression level down (FC , 0.67 and P , 0.05). 
The LOC440995 gene is located at 3q29; however, 
neither its function nor annotation was clear.
The CXCL6 gene is located at 4q21, its product is 
one of the ligands for the chemokine receptor   interleukin 
8 receptor (IL8R) and it exhibits neutrophil migration 
activity. CXCL6 also has angiogenesis activity and can 
stimulate cancer cell progression.26,27 Zhu et al reported 
overexpression of CXCL6 with its receptor, IL8R, in 
hypoxic small cell lung cancer, which is an autocrine 
regulation for cell progression.28 Rubie et al observed 
an overexpression of CXCL1 and CXCL5 in CRC, but 
the level of CXCL6 was not changed.29 Our observa-
tions showed that copy number loss and low expres-
sion levels were correlated with the invasiveness of 
CRC. To understand this relationship better, we must 
further clarify the function of CXCL6 in CRC.
The SULT1B1 gene is located at 4q13.3, and is 
one of the sulfotransferase family members (SULTs). 
SULT2  mainly  contributes  to  the  metabolism  of 
steroids.30  Sulfate  conjugation  is  usually  a  kind  of 
detoxification, and sometimes activates some chemi-
cal  compound.  For  example,  the  carcinogens,  2-  am
ino-1-methyl-6-phenylimidazo(4,5-b)  pyridine  and Clinical omics analysis of colorectal cancer
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Table 2. numbers of genes in each gene set associated 
with key clinico-pathological factors.
clinicopathological 
factor
Gene set
Gene  
set I 
(cnA)
Gene  
set II 
(ec)
Gene  
set III 
cnA + ec
T1 and T2 vs.  
T3 and T4
31 118 1
T1, T2 and  
T3 vs. T4
616 82 4
n0 vs. n1  
and n2
233 65 4
M0 vs. M1 294 146 1
re- vs. re+ 702 147 4
Total 1,876 558 14
the interleukin 8 receptor (IL8R), similar to the case 
of CXCL6. Recently, overexpression of CXCL3 has 
been observed in many cancers, including esophagus 
cancer31 and breast cancer,32 and has been suggested 
as being related to cancer recurrence. However, Li 
et al reported that CXCL3 expression had no rela-
tion with remote metastasis of CRC,33 which means 
CXCL3 may have a different function in CRC. To 
clarify this matter, we need to validate the CNA and 
expression in detail, as we have planned to do for 
CXCL6.
Gene set III-n
RALBP1, TYMS, RAB12 and RNMT were extracted 
as Gene Set III-N (N0 vs. N1 and N2). These showed 
copy  number  gains  and  high  expression  levels 
(FC . 1.5 and P , 0.05).
RALBP1 is located at 18p11.3, and is known to 
play a role in anti-apoptosis function and protection 
from stress by glutathione conjugation. The expres-
sion level of RALBP1 was shown to be increased in 
many cancer cells by expression array analysis. In 
tumor cells, RALBP1 not only suppresses apopto-
sis, but is also related with transportation of chemi-
cal anti-cancer compounds. Singhal et al found that 
antisense RNA for RALBP1 in cancer cell lines or 
Table 3. List of genes in Gene Set III using each clinico-pathological classification grouping.
ncBI
gene ID Gene symbol Gene title Location
Invasion (T1 and T2 vs. T3 and T4 : Gene set III-TA)
54490 UgT2B28 UDP glucuronosyltransferase 2 family, polypeptide B28 4q13.2
Invasion (T1, T2 and T3 vs. T4 : Gene set III-TB)
440995 LOC440995 hypothetical gene supported by BC034933; BC068085 3q29
6372 CXCL6 chemokine (C-X-C motif) ligand 6  
(granulocyte chemotactic protein 2)
4q21
27284 sULT1B1 sulfotransferase family, cytosolic, 1B, member 1 4q13.3
2921 CXCL3 chemokine (C-X-C motif) ligand 3 4q21
Lymph node metastasis (n0 vs. n1 and n2 : Gene set III-n)
10928 rALBP1 ralA binding protein 1 18p11.3
7298 TYMs thymidylate synthetase 18p11.32
201475 rAB12 rAB12, member rAs oncogene family 18p11.22
8731 rnMT rnA (guanine-7-) methyltransferase 18p11.22–p11.23
Distant metastasis (M0 vs. M1 : Gene set III-M)
397 ArhgDIB rho gDP dissociation inhibitor (gDI) beta 12p12.3
Recurrence (Gene set III-Re)
6273 s100A2 s100 calcium binding protein A2 1q21
11057 ABhD2 abhydrolase domain containing 2 15q26.1
170392 OIT3 oncoprotein induced transcript 3 10q22.1
26090 ABhD12 abhydrolase domain containing 12 20p11.21
7,12-dimethylbenz(a)anthracene  gain  carcinogenetic 
function by sulfate conjugation by SULT1. High expres-
sion of SULT1B1 mRNA has been reported in normal 
colorectal samples, and it is thought to be related to 
carcinogenesis.30 Expression of SULT1B1 is a char-
acteristic for normal colorectal tissue, so repression of 
SULT1B1 along with repression of UGT2B28 in CRC 
is thought to be related to tissue dedifferentiation.
The CXCL3 gene is located at 4q21, and its prod-
uct is one of the ligands for a chemokine receptor, Yoshida et al
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cancer cells in mice suppressed cell growth, and these 
effects were much more pronounced when combined 
with other anti-cancer drugs.34
TYMS is located at 18p11.32, and is a target for 
the anti-cancer drug 5-fluorouracil (5-FU). This drug 
inhibits the reaction between deoxyuridine monophos-
phate (dUMP) and deoxythymidine monophosphate 
(dTMP), resulting in the inhibition of DNA synthesis. 
However, the expression of TYMS is up-regulated 
in most cancers, which, in turn, makes tumor cells 
resistant  to  5-FU  treatment.  Sharma  et  al  reported 
that  5-FU  resistance  was  stronger  in  patients  with 
overexpression of either TYMS mRNA or protein.35 
Although  the  relation  between TYMS  with  lymph 
node metastasis is not clear, we are now analyzing its 
relationship with cancer resistance, as we observed 
the copy number gain and overexpression of TYMS 
more frequently in advanced CRC cases.
RAB12 is located at 18p11.22, and is known as one 
of the Rab GTP-binding proteins, which is a GTPase 
with low molecular weight. The Rab GTP-binding 
protein is associated with the membrane transporter, 
and takes part in the excretion of hormones or neu-
ron messengers. Mosesson et al found that the integ-
rin molecule is transported in the direction of cancer 
invasion by endocytosis of this molecule.36 However, 
there has been no report of a direct relation between 
RAB12 and cancer. Iida reported that RAB12 is a 
vesicle-associated small GTPase that may be activate 
the transportation of the endoplasmic reticulum from 
cytosol to centrosome on the cytoskeleton.37
RNMT is located at 18p11.22-p11.23, and is known 
to play a role in the maturation of mRNA.38 but there 
has been no report about its relation to cancer.
Gene set III-M
ARHGDIB was extracted because of its copy   number 
loss  and  low  expression  level  (FC  ,  0.67  and 
P , 0.05) in Gene Set III-M (M0 vs. M1). ARHGDIB 
is located at 12p12.3, and is known as a target gene 
of transcription factor v-ets erythroblastosis virus E26 
oncogene  homolog  1  (ETS1).  Expression  of ARH-
GCIB was found in hematopoietic cells and epithelial 
cancer. ETS1 is regulated by protein kinase C, alpha 
(PKCA) and is related to cancer invasion and progres-
sion. ARHGDIB, working with vav 1 guanine nucle-
otide exchange factor (VAV1), activates the nuclear 
factor of activated T-cells 1 (NFAT1) and results in 
transcription  regulation  of  the  tumor-related  gene 
cyclooxygenase (COX2). COX2 is related to cancer 
progression, and Schunke reported that the activation 
of COX2 in breast cancer lowers the survival rate, and 
promotes metastasis to lung or bone.39 On the other 
hand, ARHGDIB also has an ability to inhibit Rho 
GTPase, which inhibits cancer invasion. This relates to 
epithelial mesenchymal transformation. Rho GTPase 
inhibitors (Rho-GDI) such as ARHGDIB bind to GDP-
bound Rho GTPase, and inhibits its function by sta-
bilizing this bound form. These findings suggest that 
changes in the expression level of ARHGDIB result in 
a positive effect for remote metastasis of cancer.39 Ota 
et al suggested that there was a relation between a low 
inhibitory effect of ARHGDIB and remote metasta-
sis,40 which supports our observations.
Gene set III-Re
S100A2 and ABHD2 had copy number gains and high 
expression levels (FC . 1.5 and P , 0.05) in Gene 
Set III-Re (No recurrence vs. recurrence). Within this 
same set, OIT3 and ABHD12 had copy number losses 
and low expression levels (FC , 0.67 and P , 0.05).
S100A2  is  one  of  the  calcium-binding  proteins 
and is located as a cluster around 1q21.3. The S100 
family bind to p53 and regulate the oligomerization 
of p53.41 Copy number gain and high expression of 
the S100 family is reported in relation with progres-
sion and recurrence of stomach cancer,42 lung cancer, 
pancreatic cancer and brain tumor.42,43 This suggests 
that S100A2 is likely to be linked with CRC.
ABHD2 is located at 15q26.1 and is a member 
of  the  abhydrolase  (ABHD)  superfamily.  Li  et  al 
reported  an  association  between ABHD6  and  can-
cer,44 but the detailed function of this gene remains 
uncertain. ABHD12 is located at 20p11.21 and also 
belongs to the abhydrolase superfamily.
OIT3 is located at 10q22.1 and is known to be 
related to hepatocyte formation and liver function,45 
but  the  details  of  this  relationship  are  also  not 
certain.
From these observations, we could extract strong 
candidate genes by comparing the relation between 
Gene Set I and Gene Set II. The number of genes in 
Gene Set III (14 genes) was much smaller than the 
number in Gene Set I (1876 genes) or Gene Set II 
(558 genes). When we used a cut-off value of only 
P , 0.05 for the expression analysis, many genes were Clinical omics analysis of colorectal cancer
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extracted, but most of them seemed to be unrelated to 
either CNA or expression change. For this reason, we 
used FC as well as P-value for the analysis.
As described previously, not all genes in Gene 
Set I had a change in expression level. This indicates 
that the copy number itself is not parallel with the 
expression  level.  Transcription  regulation  is  also 
related  to  the  expression  level,  so  changes  in  the 
upstream genes, promoter sequences and feedback 
regulators will all result in changes in the expression 
level. We also have to keep in mind that our observa-
tions were made using microarray analysis, so they 
might also be affected by alternative splicing, due 
to the design of the probes. Detailed research must 
be performed with other methods, such as Reverse 
Transcription Polymerase Chain Reaction (RT-PCR) 
or   immunostaining. CNA also has to be confirmed 
with qPCR or FISH analysis. In addition, it is neces-
sary to confirm the relation of the genes in Table 3 
using independent CRC cases as cancer markers, and 
to identify the function of each gene using molecu-
lar biological experiments before these genes can be 
used as anti-cancer drug targets.
Pollack et al found that 62% of highly amplified 
genes in breast cancer exhibit at least twofold increased 
expression.46 In our research, we could not observe this 
kind of correlation, and amplification and increased 
expression appeared to be rather independent. How-
ever, this was rather good for us, as it became a strong 
selection criterion. Stranger et al found some corre-
lation between SNPs and CNA with the expression 
levels of the gene in Hapmap samples; however, the 
overlap of the expression change between SNPs and 
CNV was small.47 This data suggests that part of the 
expression change is due to CNV but most of them are 
related to SNPs. That means the relationship between 
CNA and expression is rather weak.
We have analyzed not only CRC but also liver 
cancer and oral cancer, and observing quite different 
tendencies in each cancer. Among them, CRC was 
the most difficult cancer to analyze by single omics 
data using this method. We assume that breast can-
cer in the previous study47 show a different relation-
ship between copy number and expression than that 
of CRC.
Here, we want to emphasize that we are suggest-
ing  use  of  the  multi-omics  analysis  for  selecting 
cancer-related genes and decreasing the false positive 
signals that tend to come out of comprehensive anal-
ysis. CNA and gene expression have some relation-
ship, but are not linked directly. This means we can 
observe the results from a different perspective. As 
suggested above, it is important to validate the CNA 
and/or  expression  change,  but  we  usually  obtain 
similar results by other methods. Also as this multi-
dimensional analysis is a kind of validation and can 
reduce the false positive candidates, we think that the 
results can be used a primary indicator tool without 
validation of each gene.
We observed differences between groups TA and 
TB, especially in Gene Set III, where we classified the 
samples according to the invasiveness of the cancer 
(T1 and T2 vs. T3 and T4, and T1, T2 and T3 vs. T4). 
This means that the progression of the CRC resulted 
in changes in the genes and their expression levels.
conclusion
We analyzed the genes related to CRC that showed 
CNA by comparing CNA with clinico-  pathological 
classification.  We  also  analyzed  the  genes  that 
showed expression level changes related with CRC 
by a similar method. The combination of these two 
methods was an efficient method of selecting pos-
sible candidate genes. Each method may contain high 
background noise in an omics study, but when used 
together, especially when they are not directly related, 
we had a very effective result.
This method can enhance the efficiency of cancer 
omics analysis, and could find a new marker or target 
for CRC.
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